William D. Tap, MD

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.

This study looked at the combination of olaratumab and doxorubicin compared with doxorubicin alone as treatment for patients with advanced soft tissue sarcoma. The combination showed a 50% improvement in progression-free survival and an 11.8-month increase in overall survival.

Based on this study, the monoclonal antibody is being investigated in an ongoing phase III study and has received an FDA Breakthrough Therapy Designation.

Videos

William D. Tap, MD, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.

Olaratumab Plus Doxorubicin in Advanced Soft Tissue Sarcoma

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

When GIST respond to imatinib, an important immune-mediated response occurs. Research has shown that an immune response is often responsible for the development of resistance to drugs such as imatinib.

If a checkpoint inhibitor is given after a TKI, an improvement in the immune response is seen.

As drug resistance makes GIST difficult to treat, the hope is that combining drugs such as dastinib and ipilimumab may be a new option for patients.

William D. Tap, MD, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

The Potential to Combine KIT and CTLA-4 Blockade in Patients With GIST

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS).

Articles

William D. Tap, MD, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS).

William D. Tap, MD | Authors

Articles

Olaratumab Plus Doxorubicin in Advanced Soft Tissue Sarcoma

The Potential to Combine KIT and CTLA-4 Blockade in Patients With GIST

A Phase I Study of the CSF1R Kinase Inhibitor PLX3397 for PVNS